Abstract 782P
Background
Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. The prognosis of patients with metastatic cervical cancer is poor with a median survival of 8-13 months. Toripalimab, a humanized IgG4 antibody specific for human PD-1 receptor, was first approved to treat second-line metastatic melanoma in China in 2018. Favorable anti-tumor activity and favorable toxicities in advanced cervical cancer patients were also observed. We hence conducted this retrospective study to further assess the efficacy and safety of toripalimab combined with chemoradiotherapy in recurrent or advanced cervical cancer patients.
Methods
From Jan 1st, 2020 to Sep 31, 2020, 25 recurrent/advanced cervical cancer patients received toripalimab treatment combined with concurrent chemoradiotherapy were enrolled.
Results
As of data cutoff on Apr 30, 2020, the median follow-up time was 10.7 months (range 6.1-14.2). Of the 25 patients, 23 patients had objective responses assessed by IRC, including 16 CR (complete response) and 7 PR (partial responses). The other 2 patients were assessed as PD (progressive disease). Median DoR (duration of response) was not reached, and the 6-month DoR rate was 92%. Treatment-related adverse events (TRAEs) of any grade were observed in 21 patients (84%) of the 25 patients. TRAEs of grade ≥3 occurred in 2 patients (8%), with the most common ones being anemia (72%) or with elevated serum alkaline phosphatase (60%). Treatment interruption and discontinuation due to TRAEs occurred in 1 patient, she had serious TRAEs, but recovered one week later. Circulating tumor cells (CTC) analyses were obtained and the results will be presented at the meeting.
Conclusions
Toripalimab combined with concurrent chemoradiotherapy demonstrated promising anti-tumor activity and manageable safety profile in patients with recurrent/advanced cervical cancer, and thus might represent a novel treatment option for this patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.